CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Sees Large Drop in Short Interest

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 331,000 shares, a decrease of 42.2% from the January 31st total of 572,600 shares. Based on an average daily trading volume, of 626,400 shares, the short-interest ratio is presently 0.5 days. Approximately 28.1% of the company’s stock are short sold.

Insider Transactions at CERo Therapeutics

In other news, major shareholder Bioventures Opportunities G. Yk sold 12,368 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.00, for a total transaction of $148,416.00. Following the completion of the sale, the insider now directly owns 213,839 shares in the company, valued at $2,566,068. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 64,300 shares of company stock valued at $529,409 over the last quarter. Company insiders own 18.00% of the company’s stock.

Hedge Funds Weigh In On CERo Therapeutics

A hedge fund recently raised its stake in CERo Therapeutics stock. Avantax Planning Partners Inc. increased its stake in shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) by 89.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,585,151 shares of the company’s stock after buying an additional 1,224,021 shares during the quarter. Avantax Planning Partners Inc. owned about 172.00% of CERo Therapeutics worth $155,000 at the end of the most recent quarter. 29.64% of the stock is owned by institutional investors and hedge funds.

CERo Therapeutics Price Performance

NASDAQ CERO traded down $0.01 during mid-day trading on Tuesday, reaching $1.43. 119,028 shares of the company’s stock traded hands, compared to its average volume of 765,268. CERo Therapeutics has a 1-year low of $1.33 and a 1-year high of $1,095.00. The company has a fifty day simple moving average of $2.96 and a 200-day simple moving average of $8.76.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.